Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 13, Issue 12, 1998, Pages 3096-3102

  Holdaas, Hallvard ^a,b   Hartmann, Anders ^a   Berg, Knut Joachim ^a   Lund, Kirsten ^a   Fauchald, Per ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Albuminuria; Amlodipine; Glomerular sieving; Losartan; Non diabetic disease

Indexed keywords

AMLODIPINE; DEXTRAN; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TUBULE FUNCTION; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0031758396     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.12.3096     Document Type: Article

References (33)

1. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transpl 1995; 10: 1963 1974
2. Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76 82
3. Remuzzi A, Pericucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267-1273
4. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G. Remuzzi G. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993; 36: 36-43
5. Mosconi L, Remuzzi A, Ruggenenti P, Sangalli F, Gambara V, Remuzzi G. Glomerular size-selective dysfunction in type-2 diabetes with glomerulopathy is not ameliorated by ACE inhibition and Ca channel blockade [Abstract]. J Am Soc Nephrol 1996; 7: 1362
6. Hemmelder MH, de Zeeuw D, de Jong PE. Verapamil is not as effective as Ace inhibition in the reduction of non-diabetic proteinuria (Abstract). J Am Soc Nephrol, 1996; 7: 1334-1335
7. Hartmann A, Lund K, Hagel L et al. Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 1994; 5: 1385 1390
8. Gansevort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hyperten 1994; 12 (Suppl 2); S37 S42
9. Gansevoort RT. de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system. Kidney Int 1994; 45: 861-867
10. Nielsen S, Dollerup J, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study (Abstract). J Am Soc Nephrol 1995; 6: 646
11. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43: 346-353
12. Remuzzi A, Perico N, Amuchastegui CS et al. Short-and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-49
13. Hagel L, Hartmann A, Lund K. Analytical gel filtration of dextran for study of the glomerular barrier function. J Chromatogr 1993; 641: 63-70
14. Scott TA, Melvin EL. Determination of dextran with anthrone. Anal Chem 1953; 45: 1656-1661
15. Schreiner GE. Determination of inulin by means of resorcinol. Proc Soc Exp Biol Med 1950; 74: 117-120
16. Smith HW, Finkelstein N, Aliminose L, Crawford B, Graber M. The renal clearance of substituted hippuric acid derivate and other aromatic acids in dog and man. J Clin Invest 1945; 24: 388-404
17. Amundsen E, Putter J, Friberger P, Knös M, Larsbråten M, Claeson G. Methods for determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol 1979; 120: 83 95
18. Hartmann A, Holdaas H, Steen PA, Kiil F. Evidence for bicarbonate-dependent lithium reabsorption in dog kidneys. Acta Physiol Scand 1984; 120: 257 264
19. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965; 21: 467-480
20. Miller JC, Miller JN. Statistics for Analytical Chemistry. Ellis Horwood, Chichester, 1986; 56-57
21. Kon V, Fogo A, Ichikawa I, with technical assistance of Helling AE, Bills T. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545 550
22. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 1994; 45: 861-867
23. Gansevoort RT, de Zeew D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 579 584
24. Mogensen CE, Sølling K. Studies on renal tubular protein reabsorption: partial and near-complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 37: 477-486
25. Holdaas H, Hartmann A, Lien MG et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163-170
26. Kunin CM. Chesney RW, Craig WA, England AC, Deangelis C. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-β-glucosaminidase in the general population and in patients with renal disease. Pediatrics 1978; 68: 751 760
27. Pflederer G, Baier M, Mondorf AW, Stefanescu T, Scherberich JE, Muller H. Changes in alkaline phosphatase isoenzyme pattern in urine as a possible marker for renal disease. Kidney Int 1980; 17: 242-246
28. Burnier M, Waeber B, Brunner HR. The advantages of angiotensin II antagonism. J Hypertension 1994; 12 [Suppl 2]:S7-S15
29. August P, Lenz T, Laragh JH. Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. Am J Hypertens 1993; 6: 148S-154S
30. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222
31. Zanetti-Elshater F, Pingitore R, Beretta-Piccoli C, Riesen W, Heinen G. Calcium antagonists for treatment of diabetesassociated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens 1994; 7: 36-45
32. Ranieri G, Andriani A, Lamontanara G, De Cesaris R. Effect of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 1994; 56: 323-330
33. Kloke HJ, Branten AJ, Huysmans FT, Wtzels JF. Antihypertensive treatment of patients with proteinuric renal diseases; Risks or benefits of calcium channel blockers? Kidney Int 1998; 53: 1559 1573